All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
5 warning events since 2020; the latest 2026-04-30.
From the record
MEDIROM Healthcare Technologies Inc.'s filings since 2020 show 5 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 5 times, the latest 2026-04-30) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+16.2% a year over 6 filed years; profitable in 4 of 6.
From the record
MEDIROM Healthcare Technologies Inc.'s 6 filed years say what it did: revenue went from JPY 3.9 billion in fiscal 2019 to JPY 8.3 billion in fiscal 2024, up 16.2% a year; it rose in 3 of 5 years; the deepest fall was 14% from fiscal 2019 to fiscal 2020; net income was positive in 4 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 6.3% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2024-12-31, MEDIROM Healthcare Technologies Inc.'s diluted share count grew about 6.3% a year, and dividends and buybacks returned about 0% of its net income over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 16%: 16¢ of profit per shareholder dollar. Leverage 88%: owes 88¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2024-12-31, MEDIROM Healthcare Technologies Inc. earned about 16 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 28 cents per dollar of everything the company owns. Leverage: it owed about 88 cents per dollar of assets, and net share issuance: its share count grew 13.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 32% of 11 in its family; net margin 1.8%.
From the record
MEDIROM Healthcare Technologies Inc.'s standing among 11 graded names in its industry family: revenue of JPY 8.3 billion in fiscal 2024 is not ranked by size, since the family reports in another currency; a net margin of 1.8% ranks in the bottom 41%; revenue growth of 15.3% a year over the last 3 filed years ranks in the top 5% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 4.7/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: MEDIROM Healthcare Technologies Inc.'s leadership is put at 4.7 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 10 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 35% of 10 in its family for room to expand.
From the record
MEDIROM Healthcare Technologies Inc.'s room to grow, from the newest filed statements (fiscal 2024): cash of JPY 329 million against debt of JPY 1.4 billion leaves -13% of its assets as net cash, bottom 45% of its family; cash from operations less capital spending is -16.9% of revenue (bottom 15%); a gross margin of 27.1% (bottom 44%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 32% of 10 in its family for growth drivers.
From the record
MEDIROM Healthcare Technologies Inc.'s growth drivers, from the filed years to fiscal 2024: revenue grew 15.3% a year over the last three filed years against 16.2% over all 6, slowing (top 25% of its family); the newest year grew 21.5% (top 5%); capital spending grew -9.3% a year (bottom 35%) (its annual reports). MEDIROM Healthcare Technologies Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 18% of 10 in its family for expectations against reality.
From the record
MEDIROM Healthcare Technologies Inc.'s newest year against its own record: revenue of JPY 8.3 billion in fiscal 2024 came in 8.2% above the JPY 7.7 billion its prior three years' pace pointed to (top 25% of its family); net income of JPY 149 million against a prior three-year average of JPY 242 million (top 5%); a net margin of 1.8% against -4.8% before (top 25%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made